RESEARCH ARTICLE



An evaluation of nine culturally tailored interventions designed to enhance engagement in HIV care among transgender women of colour in the United States

Gregory M. Rebchook^{1.§} , Deepalika Chakravarty¹, Jessica M. Xavier², JoAnne G. Keatley^{1,3}, Andres Maiorana¹, Jae Sevelius¹, Starley B. Shade^{1,4} and the SPNS Transgender Women of Color Study Group¹

[§]Corresponding author: Gregory M. Rebchook, Division of Prevention Science, Department of Medicine, University of California, San Francisco, Center for AIDS Prevention Studies (CAPS) & UCSF Prevention Research Center, UCSF Box 0886, 550 16th Street, 3rd Floor, San Francisco, CA 94143, USA. Tel: 1-415-502-1000 x 14621. (greg.rebchook@ucsf.edu)

Abstract

Introduction: Transgender women (TW) worldwide have a high prevalence of HIV, and TW with HIV encounter numerous healthcare barriers. It is critical to develop evidence-informed interventions to improve their engagement in healthcare to achieve durable viral suppression (VS). We evaluated whether participation in one of nine interventions designed specifically for TW was associated with improved engagement in HIV care among transgender women of colour (TWC).

Methods: Between 2013 and 2017, nine US organizations implemented nine distinct and innovative HIV care engagement interventions with diverse strategies, including: individual and group sessions, case management and navigation, outreach, drop-in spaces, peer support and/or incentives to engage TWC with HIV in care. The organizations enrolled 858 TWC, conducted surveys, captured intervention exposure data and extracted medical record data. Our evaluation of the interventions employed a pre-post design and examined four outcomes—any HIV care visit, antiretroviral therapy (ART) prescription, retention in HIV care and VS (both overall and among those with a clinic visit and viral load test), at baseline and every 6 months for 24 months. We employed logistic generalized estimating equations to assess the relative odds of each outcome at 12 and 24 months compared to baseline.

Results: Overall, 79% of participants were exposed to at least one intervention activity. Over 24 months of follow-up, participants received services for a median of over 6 hours (range: 3-69 hours/participant). Compared to baseline, significantly (p<0.05) greater odds were demonstrated at both 12 and 24 months for three outcomes: prescription of ART (ORs: 1.42 at 12 months, 1.49 at 24 months), VS among all participants (ORs: 1.49, 1.54) and VS among those with a clinic visit and viral load test (ORs: 1.53, 1.98). The outcomes of any HIV care visit and retention in HIV care had significantly greater odds (ORs: 1.38 and 1.58, respectively) only at 12 months compared to baseline.

Conclusions: These evaluation results illustrate promising approaches to improve engagement in HIV care and VS among TWC with HIV. Continued development, adaptation and scale-up of culturally tailored HIV care interventions for this key population are necessary to meet the UNAIDS 95-95-95 goals.

Keywords: transgender persons; HIV infections; delivery of healthcare; acquired immunodeficiency syndrome; continuity of patient care; evidence-informed interventions

Additional information may be found under the Supporting Information tab of this article.

Received 11 January 2022; Accepted 2 August 2022

Copyright © 2022 The Authors. *Journal of the International AIDS Society* published by John Wiley & Sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

1 | INTRODUCTION

Transgender women (TW) are highly impacted by HIV worldwide and in the United States. Global HIV prevalence estimates among TW range from 19.9% to 40% [1, 2]. In the United States, HIV prevalence estimates among TW range from 14% to 42% [3, 4]. Transgender women of colour (TWC) have the highest prevalence of HIV in the United States, with 44.2% among African American TW and 25.8% among Latina TW [3].

Despite this disproportionate HIV burden, TW overall and TWC specifically have been overlooked in HIV surveillance,

prevention, and treatment efforts. Until 2020, HIV surveillance in the United States did not separately monitor HIV incidence, prevalence, and mortality among TW [5]. Only a small number of prevention interventions, most developed in the past decade, have specifically addressed TWC [6–12]. In the absence of systematic national surveillance, the lack of a coordinated response to HIV disparities among TWC, and the ongoing epidemic of anti-transgender violence [13–15], the devastating impact of HIV among TWC became a silent tragedy [16].

TWC with HIV face many barriers to engagement in HIV care and treatment. Intersectional stigmas [17], including transphobia, racism, discrimination, hostility, and provider bias, produce systemic barriers to care, such as poverty, homelessness, unemployment, and lack of insurance [18-21]. The Ryan White HIV/AIDS Program (RWHAP), administered by the US Health Resources and Services Administration (HRSA), funds HIV care and treatment for low-income persons. In 2020, about 1.8% of all RWHAP clients were TW [22]. Compared to their cisgender peers, TW RWHAP clients are more likely to be of colour, be younger, have unstable housing, and have incomes at or below the federal poverty level [22, 23]. They are also more likely to report unmet needs for food and nutrition, harm reduction, mental health, and housing services at entry into HIV care compared with cisgender women and men [24]. From 2016 to 2020, TW demonstrated retention in HIV care (range: 77.3-79.8%) close to the average for all RWHAP clients (79.4-81.7%), but they have notably lower than average viral suppression (VS; 79.0-84.2% vs. 84.9-89.4%) [22].

To address these disparities, the RWHAP funded a Special Program of National Significance (SPNS), *Enhancing Engagement and Retention in Quality HIV Care for Transgender Women of Color* in 2012. The RWHAP's SPNS Program has funded demonstration projects to improve HIV care engagement since 1991 [25]. SPNS interventions have pioneered behavioural and treatment approaches to improve access to and engagement in care and HIV service delivery for diverse populations [26–33]. Until HRSA funded this initiative, there were no interventions focused upon improving TW's access to HIV primary care [34]. Nine demonstration projects were funded to develop and implement culturally tailored interventions to enhance engagement in HIV care among TWC with HIV. In this paper, we present the findings from the evaluation of health outcomes associated with these nine interventions.

2 | METHODS

2.1 | Settings and populations

The nine demonstration sites were located in four US urban centres: New York City, New York (Community Health Network in Queens and the State University of New York [SUNY]—Downstate in Brooklyn), Chicago, Illinois (Chicago House and Howard Brown Health Center), Los Angeles, California (Bienestar Human Services and Friends Research Institute) and California's San Francisco Bay area (Tri City Health Center in Fremont, Public Health Institute in Oakland and a partnership between the San Francisco Department of Health and the Asian/Pacific Islander Wellness Center in San Francisco). Additionally, HRSA funded the University of California, San Francisco to provide technical assistance and perform a multisite evaluation of the nine interventions.

2.2 | Recruitment and eligibility

The sites used multiple recruitment and intervention strategies [35], including community outreach, social network recruitment, printed materials and referrals from clinics and other service providers to recruit participants into their interventions. To be eligible, participants had to be assigned male sex at birth; identify as transgender or female; and be at least 18 years old, living with HIV, and fluent in English or Spanish. Participants provided informed consent at enrolment. The study was approved annually by the Institutional Review Boards of each site and the evaluation centre.

2.3 | Interventions

Intervention manuals are available that describe each of these nine interventions [36], and Table 1 provides an overview of the underlying theories and central components of each intervention. The interventions dynamically evolved over time—starting and stopping group sessions, adding new incentives, modifying modes of outreach, varying drop-in hours, locations and policies—to meet participants' needs.

2.4 | Evaluation

Data were collected from December 2013 to August 2017 from three sources.

2.4.1 | Participant survey

Prior to their first interaction with the intervention, participants were interviewed by non-intervention staff or completed a self-administered baseline survey in REDCap [37, 38] in the language of their choosing (English or Spanish). The survey included questions about demographic and psychosocial characteristics, as well as gender-affirming and HIV care. Participants were paid \$25-\$40 for baseline survey completion.

2.4.2 | Medical chart data from electronic health systems

Sites that provided HIV care extracted medical chart data from all visits for all participants within each reporting period. Sites that did not provide HIV care obtained signed medical release forms from each participant and obtained medical record data from their HIV care providers. The 6 months prior to enrolment was treated as the baseline period. Data were also extracted for every succeeding 6-month period through the end of the study.

2.4.3 | Intervention exposure data

Participants' exposure to the intervention was recorded in real-time by research staff at each site. Here, we use data from the first 24 months following enrolment.

Intervention name	TWEET [54] ^a	INFINI-T [55]	Howard Brown ^b [56]	Trans Life Care [<mark>5</mark> 7]	Brandy Martell Project [<mark>5</mark> 8]	Trans-Access [58]	Princess Project [<mark>59</mark>]	Transactivate [60]	Alexis Project [61]
Organization (sub-population)	Community Health Network	SUNY Downstate (adolescents and young adult TW)	Howard Brown Health Center	Chicago House	Tri City Health Center ^c	San Francisco Department of Public Health/Asian Pacific Islander Wellness Center ^d	Public Health Institute (Black/African American TW)	Bienestar Health Services (Latina TW)	Friends Research Institute
Foundation for the intervention Social Cogr Trans Th	intervention Social Cognitive Theory. Trans Theoretical Model	Singer's Syndemic Theory	Community-tallored health intervention programmes that create safe spaces for transgender women	Trauma-informed, Client centred, Strengths-based, Systems theory, Harm reduction	Critical Race Theory	conco Thans-affirming care, self-actualizing services, mindful medicine, care coordination and continuity, harm reduction, community centred, radical	Motivational Enhancement Therapy, Motivational interviewing	Trans Theoretical Model, Strengths-based perspective	Social Network Engagement, Social Cognitive Theory, Contingency Management/behavioural economics
Intervention activities	50					nearmcare			
Individual-level	Navigation by patient	Transgender peer youth	Ð	HIV care	Peer advocates and	Individualized, hands-on	Six Motivational	Peer navigation to	Peer navigator to develop
services	services specialist and	advocates facilitated		coordination/peer	health educators	support to clients to	Enhancement	guide clients	client-centred treatment plans
	retention specialist	linkage and retention in		resource navigation	provided	improve follow-through	Intervention (MEI)	through Los	and link participants to
	Assistance with benefits,	HIV care		On-site medical services	navigation	on care plans	sessions	Angeles's complex	healthcare and/or other services
	name change, gender	Social work		provided by a local	services	Supplemental mental	In-hand referrals to	medical system and	
	marker, referrals for	sessions-screening,		clinic.	Counselling and	health support services	needed services at	ensure engagement,	
	trans-affirming surgeries,	referrals for mental		Assistance with housing,	case management	Case manager to provide	partner agencies	re-engagement and	
	referral to comprehensive	health and substance		legal and employment	Direct legal counsel	consistent support		retention in HIV	
	legal services and	use services.		issues				care.	
	trans-sensitive shelters	Case management						Motivational	
	and housing specialists							interviewing-based linkage	
Small group	Series of five	One session of	Weekly youth group and	NA	16-session	The first hour of weekly	Weekly support group	NA	NA
sessions	peer-facilitated "teach	psychoeducational group	biweekly adult group		workshop with	drop-in clinic was			
	back" groups focused on				five tracks	devoted to a trans-led			
	HIV/AIDS/STDs, sexual					support group			
	health, transitioning,								
	wellness and mental								
	1 - 101								

Intervention name	TWEET [54] ^a	INFINI-T [55]	Howard Brown ^b [56]	Trans Life Care [57]	Brandy Martell Project [58]	Trans-Access [58]	Princess Project [59]	Transactivate [60]	Alexis Project [61]
Outreach (OR)	Weekly non-traditional outreach and hosted social events	Worked with a community partner to provide outreach and engagement	Community outreach at trans events and venues	Event and street-based OR	Social network recruitment: strreet, online and venue-based OR; OR to referral agencies	OR to clients out of care or needing additional support (e.g. home visits)	Community, social network and online outreach and referral coupons	Social network testing mobile testing, social network engagement, promotional materials to medical	Community-wide social network recruitment, venue and street-based OR, publicity materials, in-reach and work with community partners to increase referrals
Drop-in centre	ЧЧ.	¥.	A biweekly evening trans-only drop in called "After Hours" that provided medical, pharmacy, needle exchange and behavioural healthcare, staff and community-led programming, insurance counselling and dinner	Weeky Tans Safe resource drop-in centre and on-site medical services	¥ Z	A weekly "Trans-Access" clinic that provided comprehensive care and support services in a safe, welcoming and respectful setting	Butterfly nest: a safe space where participants and community members came to relax, take workshops and participate in support groups	providers	₹.
Incentives offered	Participants received small	AN	NA	ΔA	Participants	NA	Participants received a	Participants received a	Escalating valued gift cards to
to promote	incentives for bringing in				received a \$50		\$20 gift card for each	\$50 gift card after	incentivize both clinic
engagement in care, participation	peers to the intervention				gift card for each peer		successful referral (up to 3/participant)	their referred client was active in the	attendance and achieving HIV milestones (\$500 maximum for
in activities or					brought into the		Participants received a	programme for 6	reaching all targeted HIV
engaging peers in					intervention.		\$20 gift card for each	months.	health-promoting goals)
the intervention					Participants received a \$100		MEI session Participants received a	Participants received a \$10 gift card for	
					gift card.		\$50 gift card for	enrolment	
							completing clinic visits		

Note: Behind the scenes components (e.g. community trainings and community advisory boards) are not included as intervention components in this table.

^aReferences after each intervention name are their peer-reviewed published results.

^bThe intervention implemented by the Howard Brown Community Health Center did not have a stand-alone identity. It was a combination of the After Hours Clinic and the TYRA and T-Time support groups ^cThe Tri City Health Center is now called Bay Area Community Health.

^dThe Asian Pacific Islander Wellness Center is now called the San Francisco Community Health Center.

^eBehavioural health, linkage to care, retention in care and case management services were all available on site at Howard Brown as part of its regular suite of services. Abbreviations: MEI, Motivational Enhancement Intervention; NA, not applicable: OR, outreach; STDs, sexually transmitted diseases, TW, transgender women.

2.5 | Measures

Participant survey measures have been previously described [39]. In brief, demographic data included age, race/ethnicity, education, and financial insecurity in the past 6 months. Other baseline information categorized in a binary format (0 = No or missing, 1 = Yes) included homelessness in the past 6 months, exchange of sex to pay for necessities in the past 6 months, incarceration in the past 6 months, lack of transportation leading to a missed medical appointment in the past 12 months, presence of significant depression [40–42], gender-based discrimination experienced in the past 6 months in employment and housing [43], ever experiencing transphobia [44], disclosure of transgender identity, disclosure of HIV status, and hormone use in the past 6 months. A healthcare empowerment score was also calculated (range: 1–5) [45].

Intervention exposure data included the date of exposure, length of exposure in minutes, and type(s) of contact (community outreach, individual face-to-face session, small group session, drop-in centre or other individual virtual contact [e.g. telephone call, text message, email, social network site or postal mail]).

Medical chart data from electronic health record systems were used to create the following binary outcome variables (0 = No or missing, 1 = Yes):

- Any HIV care visit: The participant had an HIV outpatient ambulatory health services (OAHS) visit in the past 6 months.
- Antiretroviral therapy (ART) prescription: The participant had been prescribed ART in the past 6 months.
- Retention in HIV care: In the past 12 months, the participant had at least one OAHS visit in each 6-month period with a minimum of 60 days between the first visit in the first 6-month period and the last visit in the subsequent 6-month period [46]. These calculated values were unavailable at baseline as we only recorded medical chart data during the 6-month period preceding enrolment.
- VS: The participant had at least one HIV viral load test in the past 6 months and had a suppressed viral load (<200 copies/ml) at their last test in that period.
- VS among those with an OAHS visit and viral load test: Among participants who had both an OAHS visit and a viral load test in the past 6 months, the participants had a suppressed HIV viral load (<200 copies/ml) at their last test in the period. This variable represents the HRSA indicator for VS among RWHAP participants [46].

2.6 | Analysis

Using information from baseline participant surveys, we computed descriptive statistics for the overall sample and by the site.

Using intervention exposure data, we assessed the proportion of participants who received any component of the intervention, the median and inter-quartile range of the overall duration of interaction with the intervention, the proportion of participants who had each type of interaction (outreach, individual, group, drop-in and virtual), and the median number of interactions of each type.

Using medical chart data, we computed the proportion of patients who had any HIV care visit, had an ART prescription, were retained in HIV care and had verification of VS (both overall and among those with an OAHS visit and viral load test) at baseline and each 6-month period through 24 months of follow-up. Using data from each site, we employed logistic generalized estimating equations (GEE) to assess the odds of each outcome at the 12- and 24-month follow-up intervals compared to baseline. These models included a linear variable for months-since-baseline ("period") as well as a guadratic variable ("period"*"period") for months-since-baseline-squared to represent the curvilinear relationship between follow-up time and the primary outcomes. We present unadjusted odds ratios and their 95% confidence intervals (CI). Next, we employed inverse probability of treatment weighting to assess whether the observed results were due to differences in participant characteristics at baseline. We employed logistic GEE models to estimate the probability of each participant being from their observed site given the observed distribution of participant characteristics across all sites. In these models, the sample for each site is compared to the total sample across all sites. These models included participant characteristics previously found to be associated with engagement in HIV care in our sample [39]. These control characteristics are listed in Table 2. We employed multiple imputation for missing data. Next, we used the results from each model (the predicted probability of being from each site among individuals from that site) to compute the weight for each individual from each site (weight = 1/predicted probability). This weight was then applied in a weighted GEE model as defined above. The result of these models is to create pseudo-populations where the distribution of participant characteristics is similar across each site. These models have wider confidence limits compared to unweighted models as they employ re-sampling (n =100 iterations) to impute missing data and estimate weights. We present the adjusted odds ratios and their 95% CIs from these models in the Supplementary Materials. All analyses were performed in SAS 9.4 [47].

3 | RESULTS

3.1 | Participant characteristics

At baseline, the 858 participants' median age was 36 years (Table 2). Almost half of the participants identified as Hispanic, Latina or of Spanish origin, and 42% identified as Black, non-Hispanic. Two of every five participants reported having less than a 12th-grade education. Additional participant characteristics are discussed in the Supplementary Materials.

3.2 | Intervention exposure

During the first 24 months of follow-up, 79% of participants had at least one interaction with intervention staff (Table 3). Most sites had over 90% participation in intervention components. Interventions that had lower-than-average participation included Trans Life Care, Howard Brown, and Trans Access, which implemented system-level interventions that provided

	10000	1,4,5		Howard		Trans	Brandy Martell	Princess	T	Alexis
	overall n (%)	1 WEE1 n (%)	n (%)	brown n (%)	n (%) n (%)	Access n (%)	Project n (%)	Project n (%)	ıransactıvate n (%)	Project n (%)
Race-ethnicity										
Hispanic, Latina or of	417 (48.6%) 144 (88.9%)	144 (88.9%)	11 (47.8%)	20 (19.2%)	6 (5.0%)	12 (22.2%)	14 (30.4%)	8 (13.3%)	150 (100%)	52 (37.4%)
Spanish origin										
Black, non-Hispanic	364 (42.4%)	7 (4.3%)	11 (47.8%)	73 (70.2%)	113 (94.2%)	28 (51.9%)	32 (69.6%)	48 (80.0%)		52 (37.4%)
American Indian or Alaska	9 (1.0%)									9 (6.5%)
Native, non-Hispanic										
Asian or Pacific Islander,	14 (1.6%)			2 (1.9%).		8 (14.8%)		1 (1.7%)		3 (2.2%)
non-Hispanic										
Additional, non-Hispanic	11 (1.3%)	3 (1.9%)								8 (5.8%)
Multiracial, non-Hispanic	28 (3.3%)	1 (0.6%)		7 (6.7%)	1 (0.8%)	4 (7.4%)		3 (5.0%)		12 (8.6%)
No response	15 (1.7%)	7 (4.3%)	1 (4.3%)	2 (1.9%)		2 (3.7%)				3 (2.2%)
Education										
Less than grade 12	346 (40.3%)	79 (48.8%)	8 (34.8%)	22 (21.2%)	29 (24.2%)	14 (25.9%)	19 (41.3%)	23 (38.3%)	99 (66.0%)	53 (38.1%)
Completed grade 12	291 (33.9%)	39 (24.1%)	9 (39.1%)	34 (32.7%)	73 (60.8%)	24 (44.4%)	17 (37.0%)	17 (28.3%)	33 (22.0%)	45 (32.4%)
At least some college	195 (22.7%)	29 (17.9%)	6 (26.1%)	45 (43.3%)	18 (15.0%)	16 (29.6%)	9 (19.6%)	19 (31.7%)	14 (9.3%)	39 (28.1%)
No response	26 (3.0%)	15 (9.3%)		3 (2.9%)			1 (2.2%)	1 (1.7%)	4 (2.7%)	2 (1.4%)
Ran out of money for basics (past 6 months)?	(past 6 months	<i>.</i> (
Yes	560 (65.3%)	100 (61.7%)	17 (73.9%)	72 (69.2%)	67 (55.8%)	33 (61.1%)	32 (69.6%)	38 (63.3%)	93 (62.0%)	108 (77.7%)
No	180 (21.0%)	44 (27.2%)	4 (17.4%)	16 (15.4%)	37 (30.8%)	11 (20.4%)	7 (15.2%)	2 (3.3%)	47 (31.3%)	12 (8.6%)
No response	118 (13.8%)	18 (11.1%)	2 (8.7%)	16 (15.4%)	16 (13.3%)	10 (18.5%)	7 (15.2%)	20 (33.3%)	10 (6.7%)	19 (13.7%)
Ever homeless (past 6 months)?	IS)?									
Yes	352 (41.0%)	66 (40.7%)	8 (34.8%)	28 (26.9%)	69 (57.5%)	24 (44.4%)	19 (41.3%)	26 (43.3%)	39 (26.0%)	73 (52.5%)
No	381 (44.4%)	68 (42.0%)	13 (56.5%)	49 (47.1%)	35 (29.2%)	23 (42.6%)	24 (52.2%)	17 (28.3%)	104 (69.3%)	48 (34.5%)
No response	125 (14.6%)	28 (17.3%)	2 (8.7%)	27 (26.0%)	16 (13.3%)	7 (13.0%)	3 (6.5%)	17 (28.3%)	7 (4.7%)	18 (12.9%)

Table 2. Sample characteristics-overall and by demonstration site

ntinued)
ပ္ပိ
ы Сі
e
q
Ъ

							Brandy			
				Howard		Trans	Martell	Princess		Alexis
	Overall n (%)	TWEET n (%)	INFINI-T n (%)	Brown n (%)	Trans Life Care n (%)	Access n (%)	Project n (%)	Project n (%)	Transactivate n (%)	Project n (%)
Exchanged sex to pay for necessities (past 6 months)?	ecessities (past 6	i months)?								
Yes	330 (38.5%)	59 (36.4%)	7 (30.4%)	23 (22.1%)	68 (56.7%)	25 (46.3%)	20 (43.5%)	29 (48.3%)	45 (30.0%)	54 (38.8%)
No	400 (46.6%)	75 (46.3%)	13 (56.5%)	53 (51.0%)	35 (29.2%)	24 (44.4%)	22 (47.8%)	17 (28.3%)	98 (65.3%)	63 (45.3%)
No response	128 (14.9%)	28 (17.3%)	3 (13.0%)	28 (26.9%)	17 (14.2%)	5 (9.3%)	4 (8.7%)	14 (23.3%)	7 (4.7%)	22 (15.8%)
Incarcerated (past 6 months)?	s)?									
Yes	83 (9.7%)	12 (7.4%)	2 (8.7%)	2 (1.9%)	10 (8.3%)	13 (24.1%)	6 (13.0%)	6 (10.0%)	13 (8.7%)	19 (13.7%)
No	665 (77.5%)		18 (78.3%)	80 (76.9%)	94 (78.3%)	35 (64.8%)	39 (84.8%)	42 (70.0%)	134 (89.3%)	97 (69.8%)
No response	110 (12.8%)	24 (14.8%)	3 (13.0%)	22 (21.2%)	16 (13.3%)	6 (11.1%)	1 (2.2%)	12 (20.0%)	3 (2.0%)	23 (16.5%)
Missed medical visit due to lack of transportation (past 12 m	lack of transpor	tation (past 12	months)?							
Yes	202 (23.5%)	32 (19.8%)	2 (8.7%)	23 (22.1%)	17 (14.2%)	16 (29.6%)	15 (32.6%)	14 (23.3%)	33 (22.0%)	50 (36.0%)
Never/rarely	515 (60.0%)	104 (64.2%)	18 (78.3%)	60 (57.7%)	82 (68.3%)	31 (57.4%)	27 (58.7%)	24 (40.0%)	105 (70.0%)	64 (46.0%)
No response	141 (16.4%)	26 (16.0%)	3 (13.0%)	21 (20.2%)	21 (17.5%)	7 (13.0%)	4 (8.7%)	22 (36.7%)	12 (8.0%)	25 (18.0%)
Significant depression?										
Yes	449 (52.3%)	83 (51.2%)	7 (30.4%)	43 (41.3%)	68 (56.7%)	30 (55.6%)	25 (54.3%)	23 (38.3%)	82 (54.7%)	88 (63.3%)
No	309 (36.0%)	61 (37.7%)	14 (60.9%)	38 (36.5%)	39 (32.5%)	17 (31.5%)	19 (41.3%)	20 (33.3%)	64 (42.7%)	37 (26.6%)
No response	100 (11.7%)	18 (11.1%)	2 (8.7%)	23 (22.1%)	13 (10.8%)	7 (13.0%)	2 (4.3%)	17 (28.3%)	4 (2.7%)	14 (10.1%)
Disclosed transgender identity?	city?									
Yes	576 (67.1%)	104 (64.2%)	18 (78.3%)	53 (51.0%)	87 (72.5%)	34 (63.0%)	35 (76.1%)	45 (75.0%)	122 (81.3%)	78 (56.1%)
No	131 (15.3%)	29 (17.9%)	1 (4.3%)	20 (19.2%)	15 (12.5%)	7 (13.0%)	4 (8.7%)	5 (8.3%)	13 (8.7%)	37 (26.6%)
No response	151 (17.6%)	29 (17.9%)	4 (17.4%)	31 (29.8%)	18 (15.0%)	13 (24.1%)	7 (15.2%)	10 (16.7%)	15 (10.0%)	24 (17.3%)
Disclosed HIV status?										
Yes	536 (62.5%)	95 (58.6%)	13 (56.5%)	55 (52.9%)	78 (65.0%)	34 (63.0%)	27 (58.7%)	41 (68.3%)	112 (74.7%)	81 (58.3%)
No	183 (21.3%)	39 (24.1%)	5 (21.7%)	22 (21.2%)	23 (19.2%)	9 (16.7%)	12 (26.1%)	7 (11.7%)	31 (20.7%)	35 (25.2%)
No response	139 (16.2%)	28 (17.3%)	5 (21.7%)	27 (26.0%)	19 (15.8%)	11 (20.4%)	7 (15.2%)	12 (20.0%)	7 (4.7%)	23 (16.5%)
										(Continued)

Table 2. (Continued)

Overall I/WELI INTINI-I Brown Irans Life Care Access Project		-			Howard	(Trans	Brandy Martell	Princess	:	Alexis
63 (38.9%) 16 (69.6%) 58 (55.8%) 49 (40.8%) 30 (55.6%) 25 (54.3%) 91 (56.2%) 7 (30.4%) 58 (55.8%) 59 (49.2%) 18 (33.3%) 18 (39.1%) 8 (4.9%) 7 (30.4%) 32 (30.8%) 59 (49.2%) 6 (11.1%) 3 (6.5%) 52 (32.1%) 12 (52.2%) 48 (46.2%) 63 (52.5%) 28 (51.9%) 30 (55.2%) 30 (18.5%) 2 (8.7%) 32 (30.8%) 21 (17.5%) 12 (22.2%) 6 (13.0%) 72 (44.4%) 6 (26.1%) 20 (19.2%) 38 (31.7%) 21 (38.9%) 10 (21.7%) 60 (37.0%) 16 (69.6%) 56 (53.8%) 64 (53.3%) 24 (44.4%) 31 (67.4%) 30 (18.5%) 1 (4.3%) 28 (25.9%) 18 (15.0%) 47 (87.0%) 41 (89.1%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 11 (9.2%) 24 (44.4%) 3 (65.2%) 30 (18.5%) 1 (4.3%) 28 (25.9%) 100 (83.3%) 47 (87.0%) 41 (89.1%) 3 (1.9%) 4 (17.4%) 7 (6.7%) 11 (9.2%) 3 (5.5%) 2 (4.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.5%) 2 (4.3%) 36.5 (30-47) 24 (22-26) 3 (10,0R) Median (10,0R		Overall n (%)	I WEE I n (%)	n (%) n	Brown n (%)	Irans Life Care n (%)	Access n (%)	Project n (%)	Project n (%)	Iransactivate n (%)	Project n (%)
63 (38.9%) 16 (69.6%) 58 (55.8%) 49 (40.8%) 30 (55.6%) 25 (54.3%) 91 (56.2%) 7 (30.4%) 32 (30.8%) 59 (49.2%) 18 (33.3%) 18 (33.3%) 18 (39.1%) 8 (4.9%) 7 (30.4%) 32 (30.8%) 59 (49.2%) 18 (33.3%) 18 (39.1%) 8 (4.9%) 9 (39.1%) 14 (13.5%) 12 (10.0%) 6 (11.1%) 3 (6.5%) 80 (49.4%) 9 (39.1%) 24 (23.1%) 36 (30.0%) 14 (25.9%) 10 (21.7%) 52 (32.1%) 12 (52.2%) 48 (46.2%) 63 (52.5%) 28 (51.9%) 30 (65.2%) 30 (18.5%) 2 (8.7%) 32 (30.8%) 21 (17.5%) 12 (22.2%) 41 (3.0%) 72 (44.4%) 6 (26.1%) 20 (19.2%) 38 (31.7%) 21 (38.9%) 10 (21.7%) 50 (37.0%) 16 (69.6%) 56 (53.8%) 54 (53.3%) 21 (175.5%) 5 (10.9%) 30 (18.5%) 16 (69.6%) 56 (53.8%) 18 (15.0%) 21 (38.9%) 10 (21.7%) 30 (18.5%) 16 (69.6%) 56 (53.8%) 54 (13.6%) 21 (67.4%) 31 (67.4%) 30 (18.5%) 16 (69.6%) 58 (26.9%) 1	Taken hormones (past 6 moi	nths)?									
91 (56.2%) 7 (30.4%) 32 (30.8%) 59 (49.2%) 18 (33.3%) 18 (33.3%) 18 (39.1%) 8 (4.9%) 9 (39.1%) 14 (13.5%) 12 (10.0%) 6 (11.1%) 3 (6.5%) 80 (49.4%) 9 (39.1%) 24 (23.1%) 36 (30.0%) 14 (25.9%) 10 (21.7%) 52 (32.1%) 12 (52.2%) 48 (46.2%) 63 (52.5%) 28 (51.9%) 30 (65.2%) 30 (18.5%) 2 (8.7%) 32 (30.8%) 21 (17.5%) 12 (22.2%) 6 (13.0%) 72 (44.4%) 6 (26.1%) 20 (19.2%) 38 (31.7%) 24 (44.4%) 31 (67.4%) 60 (37.0%) 16 (69.6%) 56 (53.8%) 64 (53.3%) 24 (44.4%) 31 (67.4%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 5 (10.9%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 3 (65%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 3 (65%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 3 (65%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 10 (83.3%)	Yes	397 (46.3%)	63 (38.9%)	16 (69.6%)	58 (55.8%)	49 (40.8%)	30 (55.6%)	25 (54.3%)	27 (45.0%)	78 (52.0%)	51 (36.7%)
8 (4.9%) 14 (13.5%) 12 (10.0%) 6 (11.1%) 3 (5.5%) 80 (49.4%) 9 (39.1%) 24 (23.1%) 36 (30.0%) 14 (25.9%) 10 (21.7%) 52 (32.1%) 12 (52.2%) 48 (46.2%) 63 (52.5%) 28 (51.9%) 30 (65.2%) 30 (18.5%) 2 (8.7%) 32 (30.8%) 21 (17.5%) 12 (22.2%) 6 (13.0%) 72 (44.4%) 6 (26.1%) 20 (19.2%) 38 (31.7%) 21 (38.9%) 10 (21.7%) 60 (37.0%) 16 (69.6%) 56 (53.8%) 64 (53.3%) 24 (44.4%) 31 (67.4%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 5 (10.9%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 31 (65.4%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 3 (65.6%) 31 (198.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 3 (65.6%) 31 (198.5%) 1 (4.3%) 28 (26.9%) 1 (10 (83.3%) 4 7 (87.0%) 3 (65.9%) 31 (198.6%) 1 (10.83.3%) 1 (10.83.3%) 2 (10.9%) 3 (65.9%) 3 (65	No	383 (44.6%)	91 (56.2%)	7 (30.4%)	32 (30.8%)	59 (49.2%)	18 (33.3%)	18 (39.1%)	15 (25.0%)	67 (44.7%)	76 (54.7%)
80 (49.4%) 9 (39.1%) 24 (23.1%) 36 (30.0%) 14 (25.9%) 10 (21.7%) 52 (32.1%) 12 (52.2%) 48 (46.2%) 63 (52.5%) 28 (51.9%) 30 (65.2%) 30 (18.5%) 2 (8.7%) 22 (30.8%) 21 (17.5%) 12 (22.2%) 6 (13.0%) 60 (37.0%) 16 (69.6%) 56 (53.8%) 64 (53.3%) 21 (47.4%) 31 (67.4%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 5 (10.9%) 15 (10.9%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 7 (16.7%) 31 (19.2%) 47 (87.0%) 24 (44.4%) 31 (67.4%) 31 (57.6%) 31 (19.6%) 11 (9.2%) 9 (15.0%) 9 (16.7%) 2 (43.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (10.9%) 7 (6.7%) 11 (9.2%) 47 (87.0%) 2 (13.9%) 7 (5.6%) 1 (100 (83.3%) 9 (7.5%) 3 (5.6%) 2 (43.3%) 9 (5.6%) 1 (4.3%) 9 (5.6%) 1 (12.5%) 9 (7.5%) 3 (100 (83.35) 41.5 (31-51) 36.5 (29-44) 31 (26.5-42.5) 2 (41.5 (100 (100 (100 (100 (100 (100 (100 (10	No response	78 (9.1%)	8 (4.9%)		14 (13.5%)	12 (10.0%)	6 (11.1%)	3 (6.5%)	18 (30.0%)	5 (3.3%)	12 (8.6%)
332 (35.2%) 80 (49.4%) 9 (39.1%) 24 (23.1%) 36 (300%) 14 (25.9%) 10 (21.7%) 0 394 (45.9%) 52 (32.1%) 12 (52.2%) 48 (46.2%) 63 (55.2%) 28 (51.9%) 30 (55.2%) 0 $response$ 162 (18.9%) 30 (18.5%) 2 (8.7%) 23 (30.0%) 14 $(25,9\%)$ 30 (55.2%) 16 $discrimination$ $past$ $months$)? 2 (18.5%) 2 (8.7%) 23 (30.0%) 12 (22.2%) 6 (13.0%) 16 $discrimination$ $past$ $months$)? 2 (18.5%) 2 (19.2%) 23 (17.5%) 21 (138.9%) 10 (21.7%) 0 $esponse$ 157 (18.5%) 16 (52.5%) 28 (12.5%) 21 (12.7%) 21 (12.7%) 0 $esponse$ 157 (18.5%) 16 (45.6%) 56 (53.3%) 21 (12.7%) 21 (23.9%) 10 (21.7%) 0 $esponse$ 157 (18.5%) 16 (29.6%) 18 (19.2%) 24 (14.4%) 31 (5.7%) 0 $esponse$ 157 18 (28.9%) 18 (18.5%) 12 (25.9%) 12 (27.9%) 21 (21.2%) 0 $esponse$ 157 16 <td>Employment discrimination (</td> <td>past 6 months)?</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Employment discrimination (past 6 months)?									
0394 (45.9%)52 (32.1%)12 (52.2%)48 (46.2%)63 (52.5%)28 (51.9%)30 (65.2%)0 response162 (18.9%)30 (18.5%)2 (8.7%)2 (8.7%)32 (30.8%)21 (17.5%)12 (22.2%)6 (13.0%)ter discrimination (past 6 months)?30 (18.5%)7 (44.4%)6 (26.1%)20 (19.2%)38 (31.7%)21 (38.9%)10 (21.7%)5283 (33.0%)72 (44.4%)6 (26.1%)20 (19.2%)54 (53.3%)64 (53.3%)21 (38.9%)10 (21.7%)5283 (33.0%)72 (44.4%)6 (37.0%)16 (69.6%)56 (53.8%)64 (53.3%)21 (38.9%)10 (21.7%)5283 (33.0%)72 (44.4%)6 (26.1%)28 (26.9%)18 (15.0%)9 (16.7%)5 (10.9%)677 (18.3%)30 (18.5%)1 (4.3%)28 (26.9%)18 (15.0%)9 (16.7%)5 (10.9%)6745 (86.8%)150 (92.6%)18 (78.3%)84 (80.8%)100 (83.3%)47 (87.0%)41 (89.1%)650 (5.8%)3 (1.9%)1 (4.3%)28 (26.9%)11 (92.2%)3 (5.5%)2 (4.3%)650 (5.8%)3 (1.9%)1 (4.3%)13 (12.5%)9 (7.5%)3 (5.5%)2 (4.3%)663 (7.3%)9 (5.6%)1 (4.3%)13 (12.5%)9 (7.5%)3 (5.6%)2 (4.3%)663 (73%)9 (5.6%)1 (4.3%)13 (12.5%)9 (7.5%)3 (5.5%)2 (4.3%)667.3%1 (4.3%)1 (2.2-26)3 (2.5-425)2 (7.5%)2 (7.3%)2 (7.3%)6<	Yes	302 (35.2%)	80 (49.4%)	9 (39.1%)	24 (23.1%)	36 (30.0%)	14 (25.9%)	10 (21.7%)	16 (26.7%)	75 (50.0%)	38 (27.3%)
o response 162 (18.9%) 30 (18.5%) 2 (8.7%) 32 (30.8%) 21 (17.5%) 12 (22.2%) 6 (13.0%) ter discrimination (past 6 months)? is 283 (33.0%) 72 (44.4%) 6 (26.1%) 20 (19.2%) 38 (31.7%) 21 (38.9%) 10 (21.7%) 28 (26.9%) 18 (15.0%) 24 (44.4%) 31 (67.4%) 20 (25.7%) 28 (26.9%) 18 (15.0%) 21 (38.9%) 10 (21.7%) 28 (26.9%) 18 (15.0%) 24 (44.4%) 31 (67.4%) 20 (esponse 157 (18.3%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 5 (10.9%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 5 (10.9%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 2 (10.7%) 5 (10.9%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 2 (10.7%) 2 (10.9%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 3 (10.9%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 9 (16.7%) 2 (10.9%) 28 (26.9%) 18 (12.0%) 13 (12.5%) 9 (7.5%) 3 (5.5%) 2 (4.3%) 0 response 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) 14 (10.7%) 10 (10.8) Median (10.	No	394 (45.9%)	52 (32.1%)	12 (52.2%)	48 (46.2%)	63 (52.5%)	28 (51.9%)	30 (65.2%)	21 (35.0%)	65 (43.3%)	75 (54.0%)
ter discrimination (past 6 months)? se discrimination (past 6 months)? se $283 (33.0\%)$ 72 (44.4%) 6 (26.1%) 20 (19.2%) 38 (31.7%) 21 (38.9%) 10 (21.7%) o response $157 (18.3\%)$ 60 (37.0%) 16 (69.6%) 56 (53.8%) 64 (53.3%) 24 (44.4%) 31 (67.4%) o response $157 (18.3\%)$ 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 5 (10.9%) experienced transphobia? so $50 (5.8\%)$ 30 (18.5%) 18 (78.3%) 84 (80.8%) 100 (83.3%) 47 (87.0%) 41 (89.1%) o response $63 (7.3\%)$ 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) herein (IQR) Median (IQR)	No response	162 (18.9%)	30 (18.5%)	2 (8.7%)	32 (30.8%)	21 (17.5%)	12 (22.2%)	6 (13.0%)	23 (38.3%)	10 (6.7%)	26 (18.7%)
38 23.0% 72 (44.4%) 6 (26.1%) 20 (19.2%) 38 (31.7%) 21 (38.9%) 10 (21.7%) 0 418 (48.7%) 60 (37.0%) 16 (69.6%) 56 (53.8%) 64 (53.3%) 24 (44.4%) 31 (67.4%) 0 response 157 (18.3%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 5 (10.9%) • experienced transphobia? 745 (86.8%) 150 (92.6%) 18 (78.3%) 84 (80.8%) 100 (83.3%) 47 (87.0%) 41 (89.1%) 0 50 (58%) 3 (1.9%) 4 (17.4%) 7 (6.7%) 11 (9.2%) 4 (74.8%) 3 (6.5%) 0 response 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) 0 response 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) 0 response 63 (7.3%) 9 (5.6%) 1 (4.3%) 1 (22.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) 0 response 63 (7.3%) 9 (16.7%) 7 (6.7%) 1 (1 (9.2%) 2 (4.3%) 0 response <td>Shelter discrimination (past</td> <td>6 months)?</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Shelter discrimination (past	6 months)?									
o 418 (48.7%) 60 (37.0%) 16 (69.6%) 56 (53.3%) 64 (53.3%) 24 (44.4%) 31 (67.4%) o response 157 (18.3%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 5 (10.9%) experienced transphobia? 745 (86.8%) 150 (92.6%) 18 (78.3%) 84 (80.8%) 100 (83.3%) 47 (87.0%) 41 (89.1%) o 50 5.8%) 3 (17.4%) 7 (5.7%) 11 (92.6%) 41 (89.1%) 5 (10.9%) 41 (89.1%) o 50 5.8%) 3 (17.4%) 7 (5.7%) 11 (92.6%) 41 (89.1%) 5 (10.9%) 41 (89.1%) 3 (5.5%) 2 41 (89.1%) 3 (5.5%) 3 (5.5%) 3 (5.5%) 3	Yes	283 (33.0%)	72 (44.4%)	6 (26.1%)	20 (19.2%)	38 (31.7%)	21 (38.9%)	10 (21.7%)	24 (40.0%)	41 (27.3%)	51 (36.7%)
o response 157 (18.3%) 30 (18.5%) 1 (4.3%) 28 (26.9%) 18 (15.0%) 9 (16.7%) 5 (10.9%) • experienced transphobia? • experienced transphobia? 745 (86.8%) 150 (92.6%) 18 (78.3%) 84 (80.8%) 100 (83.3%) 47 (87.0%) 41 (89.1%) • o 50 (5.8%) 3 (1.9%) 4 (17.4%) 7 (6.7%) 11 (9.2%) 4 (7.4%) 3 (6.5%) • o 50 (5.8%) 3 (1.9%) 4 (17.4%) 7 (6.7%) 11 (9.2%) 4 (7.4%) 3 (6.5%) • o 53 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) • o response 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) • o response 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) • o response 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) • o response 63 (7.3%) 9 (5.6%) 1 (2.5%) 1 (10R) Median (IQR) Median (IQ	No	418 (48.7%)	60 (37.0%)	16 (69.6%)	56 (53.8%)	64 (53.3%)	24 (44.4%)	31 (67.4%)	16 (26.7%)	85 (56.7%)	66 (47.5%)
 experienced transphobia? ¹ 245 (86.8%) 150 (92.6%) 18 (78.3%) 84 (80.8%) 100 (83.3%) 47 (87.0%) 41 (89.1%) ¹ 50 (5.8%) 3 (1.9%) 4 (17.4%) 7 (6.7%) 11 (9.2%) 4 (7.4%) 3 (6.5%) ¹ 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) ¹ 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) ¹ 62 (28 - 46) 36.5 (30 - 47) 24 (22 - 26) 31 (26.5 - 42.5) 27.5 (23 - 35) 41.5 (31 - 51) 36.5 (29 - 44) ¹ (3.75 - 4.75) 4 (4.5) 4 (5.75 - 4.75) 4 (3.2 - 5.5) 4 (No response	157 (18.3%)	30 (18.5%)	1 (4.3%)	28 (26.9%)	18 (15.0%)	9 (16.7%)	5 (10.9%)	20 (33.3%)	24 (16.0%)	22 (15.8%)
55 745 (86.8%) 150 (92.6%) 18 (78.3%) 84 (80.8%) 100 (83.3%) 47 (87.0%) 41 (89.1%) 60 50 (5.8%) 3 (1.9%) 4 (17.4%) 7 (6.7%) 11 (9.2%) 4 (7.4%) 3 (6.5%) 61 7335 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) 63 7.336 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) 0 response 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) 0 response 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) 0 response 63 (7.3%) 7 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) 0 response 63 (7.8%) 1 (2.9%) 1 (2.5%) 3 (5.6%) 2 (4.3%) 16 response 36 (28-46) 36.5 (30-47) 2 (22-26) 3 (26.5-42.5) 2 (7.5%) 3 (10.7) 3 (5.75, 13.6-51) 3 (5.6-51, 13.6-51) 3 (5.2-51, 13.6-51) 3 (5.2-51, 13.6-51)	Ever experienced transphobi	a?									
0 50 (5.8%) 3 (1.9%) 4 (17.4%) 7 (6.7%) 11 (9.2%) 4 (7.4%) 3 (6.5%) 0 response 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) Nedian (IQR) Median (IQR)	Yes	745 (86.8%)	150 (92.6%)	18 (78.3%)	84 (80.8%)	100 (83.3%)	47 (87.0%)	41 (89.1%)	45 (75.0%)	145 (96.7%)	115 (82.7%)
o response 63 (7.3%) 9 (5.6%) 1 (4.3%) 13 (12.5%) 9 (7.5%) 3 (5.6%) 2 (4.3%) Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR) 36 (28-46) 35.5 (30-47) 24 (22-26) 31 (26.5-42.5) 27.5 (23-35) 41.5 (31-51) 36.5 (29-44)	No	50 (5.8%)	3 (1.9%)	4 (17.4%)	7 (6.7%)	11 (9.2%)	4 (7.4%)	3 (6.5%)		4 (2.7%)	14 (10.1%)
Median (IQR) N 36 (28-46) 36.5 (30-47) 24 (22-26) 31 (26.5-42.5) 27.5 (23-35) 41.5 (31-51) 36.5 (29-44) 146-25 amonument 1 (2.75-4.75) 4 (4.5) 4 25 (275-4.75) 4 (2.45-5.5) 4 12 (2-5) 3 4 12 (2-5) 3	No response	63 (7.3%)	9 (5.6%)	1 (4.3%)	13 (12.5%)	9 (7.5%)	3 (5.6%)	2 (4.3%)	15 (25.0%)	1 (0.7%)	10 (7.2%)
36 (28-46) 36.5 (30-47) 24 (22-26) 31 (26.5-42.5) 27.5 (23-35) 41.5 (31-51) 36.5 (29-44) Theore amonomoust 1 (2.75-4.75) 4 (4.5) 4 25 (2.75-4.75) 4 (2.42-5) 2 4 (2.75-4.25) 4 22 (2.75-5) 2		Median (IQR)	Median (IQR)	Median (IQR)	Median (IQR)	Median (IQR)	Median (IQR)	Median (IQR)	Median (IQR)	Median (IQR)	Median (IQR)
オ (3 75-オ 75) オ (オ-6) オ 25 (3 75-オ 75) オ (3 53-5) オ (3 75-オ 38) オ 13 (3-5) オ 25 (3 25-5)	Age	36 (28-46)	36.5 (30-47)	24 (22-26)	31 (26.5-42.5)		41.5 (31-51)	36.5 (29-44)	41 (32.5-50) 44 (38-50)	35 (28-44)
	Healthcare empowerment	4 (3.75-4.7	5) 4 (4-5)	4.25 (3.75-4.75)	4 (3.63-5)	4 (3.75-4.38)	4.13 (3-5)	4.25 (3.25-5)	3.88 (3.25-4.2	5) 4 (4-4.5)	4 (2.75-5)

Table 3. Summary of intervention exposure

	Overall	TWEET	INFINI-T	Howard Brown	Irans Life Care	Brandy Trans Access Martell	Brandy Martell	Project	Transactivate	Alexis Project
Total participants enrolled	858	162	23	104	120	54	46	60	150	139
Participants exposed to intervention	676	152	19	20	58	39	44	57	150	137
% Exposed to intervention	79%	94%	83%	19%	48%	72%	%96	95%	100%	%66
Duration of intervention	6.2	5.17	68.75	c	6	17	10.83	4.58	7.33	3.93
exposure (in	(3 - 12)	(1.67 - 11.13)	(35.53-210.72)	(2-7)	(3-15.83)	(9.25-45)	(6.25-32.08)	(2.75-7.08)	(4.5 - 11.33)	(2.07-6.87)
hours)—median (IQR)										
% Exposed to each type of										
contact:										
Outreach	2.66					35.90				2.92
Individual session	79.88	80.92	100		1.72	94.87	36.36	100	100	100
Group session	26.33	65.13	100	70		41.03	65.91	1.75		
Drop-in session	13.17			40	98.28	48.72		8.77		
Virtual ^a	60.36	79.61	68.42		1.72	84.62	93.18	40.35	91.33	28.47
Median number of										
contacts (among										
participants with each										
type of contact):										
Outreach	1					1				1
Individual session	4	7	7		1	9	2	4	4	4
Group session	5.5	5	31			2.5	12	2		
Drop-in session	ო			2	n	9		1		
Virtual interaction ^a	ო	1	10		16	5	34	1	7	2

Rebchook GM et al. *Journal of the International AIDS Society* 2022, **25**(S5):e25991 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25991/full | https://doi.org/10.1002/jia2.25991




Figure 1. Changes in outcomes over time. Abbreviations: ART, antiretroviral therapy; OAHS, outpatient ambulatory health services; VL, viral load.

comprehensive trans-competent services. Thus, their participants often interacted with the existing care system to receive routine services (not recorded as intervention exposure), in addition to specified intervention activities (recorded as intervention exposure).

The interventions provided substantial support to participants. Participants received services for a median of over 6 hours (interquartile range = 3-12 hours) over 24 months. Median time receiving services ranged from 3 hours at Howard Brown to 69 hours (almost 3 hours per month) in INFINI-T. The majority of participants had in-person individual sessions (80%; median = 4 sessions) and/or virtual sessions (60%; median = 3 sessions), including reminder phone calls. Fewer participants were reached through group sessions (26%; median = 5.5 sessions), drop-in settings (13%; median = 3 visits) and outreach (3%; median = 1 contact).

3.3 | Overall outcomes

Figure 1 displays outcomes across all sites by follow-up period. The proportion of participants who had a suppressed viral load increased from 22% at baseline to 38% at 6 months and decreased to 35% at 24 months. Trends were similar for any HIV care visit (38% at study entry, 58% at 6 months and 47% at 24 months), prescription of ART (39% at study entry, 57% at 6 months and 53% at 24 months) and retention in HIV care (33% at 6 months, 44% at 12 months and 40% at 24 months). In contrast, among participants who had an OAHS visit in addition to a viral load test during a study period, the proportion with suppressed viral load increased during each study period from 69% at study entry to 82% at 24 months.

The GEE models revealed that these increases for the overall sample were statistically significant at 12 months for all outcomes (unadjusted odds ratio [OR] = 1.38, 95% CI = 1.10-1.74 for any HIV care visit; OR = 1.42, 95% CI = 1.07-1.89 for prescription of ART; OR = 1.58, 95% CI = 1.03-2.42for retention in HIV care; OR = 1.49, 95% CI = 1.23-1.81 for VS among all participants; and OR = 1.53, 95% CI = 1.23-1.89 for VS among those with an OAHS visit and viral load test) (Table 4). At 24 months, the increases remained significant for prescription of ART (OR = 1.49, 95% CI = 1.02–2.18), VS among all participants (OR = 1.54, 95% CI = 1.24–1.93); and VS among those with an OAHS visit and viral load test (OR = 1.98, 95% CI = 1.61–2.43).

3.4 | Outcomes by site

Table 4 also includes results from the unadjusted models for each site. We observed statistically significant (p < 0.05) increases in the odds of suppressed viral load at six of the nine sites at 12 months (Transactivate, TWEET, Alexis Project, INFINI-T, Howard Brown and Trans Access) and at four sites at 24 months (Transactivate, TWEET, Howard Brown and Trans Access). Sites where the odds of any HIV primary care visit, prescription of ART or retention in HIV primary care were significantly higher at 12 months relative to baseline, also demonstrated increased odds of VS at 12 months. Multiple sites had higher odds of any HIV visit, prescription of ART or retention in HIV care at 24 months. Of the six sites where the odds of ART prescription at 24 months were significantly higher compared to baseline, five also had significantly higher odds of VS at 24 months.

Next, we employed inverse probability weighting to examine the effect of each site's intervention on HIV care continuum outcomes, while accounting for differences in client characteristics at baseline (see Supplementary Materials). While these models had larger confidence intervals than our unadjusted model due to increased variance associated with the estimation of weights and missing data, the estimates of effect (odds ratios) were similar or larger for five of the six sites where the odds of VS increased significantly between baseline and 12 months. The odds ratio for TWEET declined 15% (from 2.67 to 2.32), but this estimate of effect remained larger than that of any other site. We observed substantially more variability in the estimates of effect for odds of VS at 24 months, likely due to differential loss-to-follow-up among clients who were less likely to remain engaged in HIV care.

outcomes
primary
Jnadjusted
Table 4. (

	At 12 months follow-up	dn-				At 24 months follow-up	d			
	Δnv visit	Prescribed ART	Ratained in HIV care	Summerseed wiral load	Suppressed viral load (among those with	Δnv. visit	Proscribed ART	Botained in HIV zace Summerced viral load	Summerced viral load	Suppressed viral load (among those with OAHS vicit)
	JIGIA ÁITH	LIGSCHINGS WIN	Verailien III LIV cale		(JISIN CLIMO	JIGIA ÁIR-			noan viiai ioan	
Overall sample	1.38 (1.10, 1.74)	1.42 (1.07, 1.89)	1.58 (1.03, 2.42)	1.49 (1.23, 1.81)	1.53 (1.23, 1.89)	1.34 (0.93, 1.92)	1.49 (1.02, 2.18)	1.73 (0.91, 3.32)	1.54 (1.24, 1.93)	1.98 (1.61, 2.43)
TWEET	3.62 (1.54, 8.50)	3.02 (2.11, 4.31)	5.42 (2.78, 10.57)	2.67 (1.90, 3.75)	2.03 (0.29, 14.05)	3.85 (1.30, 11.40)	3.91 (2.49, 6.13)	11.28 (4.78, 26.65)	2.51 (1.64, 3.85)	4.47 (0.53, 37.60)
INFINI-T	1.49 (1.15, 1.93)	1.53 (0.65, 3.57)	11.93 (2.58, 55.20)	2.39 (1.03, 5.51)	1.00 (0.53, 1.89)	1.52 (1.08, 2.13)	1.28 (0.40, 4.10)	24.98 (3.22, 193.47)	2.38 (0.77, 7.34)	1.46 (0.63, 3.39)
Howard Brown	1.81 (1.12, 2.96)	1.30 (0.78, 2.18)	1.15 (0.58, 2.26)	1.76 (1.24, 2.50)	2.09 (1.00, 4.34)	1.87 (0.96, 3.65)	2.57 (1.34, 4.93)	1.06 (0.41, 2.71)	2.01 (1.21, 3.35)	2.90 (1.11, 7.58)
Trans Life Care	1.23 (0.83, 1.83)	1.07 (0.80, 1.40)	0.85 (0.49, 1.48)	0.96 (0.71, 1.28)	1.93 (1.09, 3.41)	1.12 (0.64, 1.94)	1.15 (0.82, 1.61)	0.76 (0.37, 1.57)	1.12 (0.75, 1.68)	2.41 (1.16, 5.00)
Trans Access	1.03 (0.69, 1.54)	2.52 (1.50, 4.23)	1.73 (0.80, 3.74)	1.87 (1.11, 3.16)	0.50 (0.17, 1.50)	0.71 (0.39, 1.30)	2.87 (1.49, 5.53)	2.05 (0.72, 5.85)	2.16 (1.12, 4.19)	0.42 (0.13, 1.43)
Brandy Martell	1.28 (0.98, 1.68)	1.20 (0.82, 1.74)	1.07 (0.54, 2.12)	1.23 (0.81, 1.87)	1.87 (0.98, 3.54)	1.08 (0.76, 1.53)	1.59 (1.02, 2.47)	1.03 (0.39, 2.69)	1.32 (0.73, 2.40)	2.19 (0.95, 5.08)
Princess Project	1.02 (0.66, 1.59)	0.98 (0.69, 1.41)	1.16 (0.54, 2.50)	1.03 (0.62, 1.73)	1.82 (0.76, 4.35)	0.87 (0.47, 1.60)	0.73 (0.41, 1.30)	0.86 (0.29, 2.57)	0.70 (0.34, 1.45)	3.10 (1.19, 8.07)
Transactivate	2.31 (1.64, 3.24)	1.60 (1.22, 2.10)	1.70 (1.08, 2.68)	1.43 (1.09, 1.87)	2.27 (0.89, 5.83)	3.23 (2.06, 5.04)	1.48 (1.05, 2.09)	2.07 (1.14, 3.77)	1.56 (1.07, 2.26)	2.87 (0.85, 9.66)
Alexis Project	0.90 (0.66, 1.24)	1.33 (1.00, 1.77)	1.23 (0.74, 2.04)	1.61 (1.09, 2.39)	1.01 (0.53, 1.95)	0.82 (0.54, 1.24)	1.15 (0.80, 1.64)	1.09 (0.58, 2.02)	1.43 (0.87, 2.45)	1.58 (0.69, 3.63)
Note: Bold indicates sta	Note: Bold indicates statistically significant result ($p < 0.05$).	(p<0.05).								
Abbreviation: ART, antire	troviral therapy; OAHS, c	Abbreviation: ART, antiretroviral therapy; OAHS, outpatient ambulatory health services.	'th services.							

4 | DISCUSSION

TWC with HIV experience many direct and indirect barriers to care. The nine US-based community service providers participating in this initiative developed strategies to help TWC overcome these barriers and engage in HIV-related healthcare. Together, these clinics and community-based organizations enrolled 858 TWC with HIV, of whom over threequarters received intervention services. Despite TWC often being reluctant to engage in health-related programmes due to prior negative experiences with healthcare agencies, these organizations had great success recruiting participants and partnering with their local communities. Engaging trans women in leadership, staffing, and other meaningful roles has consistently been found to positively impact enrolment and retention in trans-specific programming [48]. These strategies were successfully employed by most of these interventions to leverage social networks, increase trust, and provide peer navigation services that maximized participants' safety and support.

Overall, the interventions achieved improvements in engagement in HIV care and VS at 12 and 24 months. Specifically, the odds of being virally suppressed at 12 and 24 months were significantly higher compared to baseline among all enrolled participants, among participants with an OAHS visit in the previous 6 months, and among participants in multiple sites (i.e. for six sites at 12 months and four sites at 24 months for VS among enrolled participants regardless of OAHS visit, and three sites each at 12 and 24 months for VS among those with an OAHS visit in the previous 6 months). This is an important success of the initiative. Of note, this improvement in VS was not always accompanied by a statistically significant improvement in retention in care suggesting that some intervention participants continued to take ART and achieved or maintained VS even if they did not always have the number and timing of appointments necessary to meet HRSA's definition of retention in care [46].

It is not surprising that sustaining engagement and retention in HIV care over 24 months was challenging since TWC with HIV experience intersectional oppression in the forms of racism and transphobia, community and institutional violence, stigma, discrimination, and marginalization from mainstream economic opportunities, which combine to adversely impact their access to healthcare and health outcomes [49]. Additional implementation research is necessary to study how interventions can be integrated into practice and maintained at the level of intensity necessary to result in sustained improvement in healthcare engagement and health outcomes over longer periods of time.

Given the challenges faced by TWC with HIV, the successes of these programmes demonstrate how well tailored they were to meet the specific needs of their communities. They are also a testament to the dedication of the intervention staff (many of whom were TWC), and the trusting relationships that developed between staff and participants [50]. While these programmes were heterogeneous in many ways, many shared important common elements. Recruiting, supporting, and retaining peer staff in HIV programming has consistently been found to contribute to positive outcomes [48]. In addition, many of these programmes aimed to

address TWC's social determinants of health and intersecting vulnerabilities, including structural barriers, such as assistance with housing, legal concerns, and employment issues, and they provided trans-affirming HIV care either on site or by referral. Indeed, the literature around health disparities increasingly acknowledges that it is critical that interventions to improve HIV-related health outcomes among marginalized populations address social and structural factors that contribute to HIV-related health disparities, rather than simply focus on individual-level behaviour change [51, 52].

Due to the variations in the design and implementation of the individual interventions, we cannot pinpoint with certainty the intervention components that contributed to improvments in HIV care. However, we believe that keys to improving VS at 24 months included having structured activities clearly defined in written intervention curricula (e.g. TWEET), creating systemic change at the organizational level to make the entire system of care responsive to the needs of TWC with HIV (e.g. Howard Brown) and offering ongoing peer navigation/case management services to facilitate linkage to and retention in care (e.g. Trans Access and Transactivate). Some interventions did not last for 24 months (e.g. the Alexis Project); thus, VS not always being sustained beyond 12 months is not surprising.

4.1 | Limitations

These findings should be interpreted in the context of certain limitations. First, the interventions were implemented in urban settings in the United States with participants whose median age was 36 years. Results may differ in programmes operating in dissimilar settings or with younger or older populations. Second, there were inconsistencies in how demonstration sites recorded various intervention activities (e.g. not all sites recorded short, virtual interactions). Therefore, we are limited in our ability to compare the effect of intervention exposure across interventions. Third, there was variability in the completeness of medical record data submitted for analysis. Thus, these results may underestimate the effect of some interventions. Fourth, one site enrolled few participants (INFINI-T). This limited our ability to evaluate the effect of this intervention in larger settings. Fifth, these interventions were designed to "float above" the existing RWHAP services that the organizations already provided. A new activity that was integral to intervention at one site might have been routinely provided at another site. In the latter instance, these existing services were not recorded as exposure to the intervention being studied, thus making direct comparisons between the interventions difficult. Sixth, the structure of the HRSA SPNS Initiative prevented a randomized controlled trial design, which is used to develop evidence-based interventions (EBIs). In addition, because of this community's great need for support, it was not viable to allocate some TWC to wait to receive these interventions. Thus, we are not able to determine whether broader changes in practice patterns or interventions external to this initiative contributed to the observed changes in engagement in HIV care. However, given the consistency of the results observed across the interventions, we are confident that these interventions enhanced engagement in HIV care among the TWC that they served.

5 | CONCLUSIONS

Based on these findings, all the evaluated interventions meet HRSA's criteria for evidence-informed interventions since they were based on theory and demonstrated improvement in at least one aspect of HIV care and treatment [35]. The evaluation results from this "real world" initiative are very promising since they documented significant improvements in engagement and retention in HIV care. ART prescriptions. and VS. Scientifically rigorous studies, such as adaptive trials or hybrid implementation science designs, could be conducted in the future on these or similar intervention models to help increase the number of EBIs that can further reduce HIV-related health disparities. This HRSA SPNS initiative presents an alternative and complementary approach to the randomized-controlled trial model to help ameliorate the research-to-practice gap and reduce health disparities among TWC with HIV. This approach is vital to eliminate inequalities that fuel the HIV/AIDS epidemic and ultimately achieve the UNAIDS 95-95-95 targets [53].

AUTHORS' AFFILIATIONS

¹Division of Prevention Science, Department of Medicine, University of California, San Francisco, California, USA; ²Independent Consultant, Silver Spring, Maryland, USA; ³Innovative Response Globally for Transgender Women and HIV (IRGT), San Francisco, California, USA; ⁴Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA

COMPETING INTERESTS

The authors declare that they have no competing interests.

AUTHORS' CONTRIBUTIONS

All authors have read and approved the final manuscript. GMR, SBS, AM, JS and JGK made substantial contributions to conceptualizing and designing the national evaluation protocol. JMX conceptualized and designed the multisite initiative. SBS and DC analysed the data. GMR, DC, JMX, JS, AM and SBS wrote the paper.

ACKNOWLEDGEMENTS

Thank you to the 858 transgender women of colour who participated in this Initiative and to the dedicated principal investigators (Robert Contreras, Judith Perloff, Luis Freddy Molano, Cathy J. Reback, Kelly Ducheny, Tooru Nemoto, Royce Lin, Jeffrey Birnbaum and Tiffany Woods), researchers and staff at each of the nine community demonstration sites.

FUNDING

This project was supported by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) under grant number U90HA24973 in the amount of \$536,244 awarded to the University of California at San Francisco.

DISCLAIMER

The views expressed in this publication are solely the opinions of the authors and do not necessarily reflect the official policies of the US Department of Health and Human Services or the Health Resources and Services Administration, nor does mention of the department or agency names imply endorsement by the US Government. This publication was also made possible with help from the UCSF-Center for AIDS Prevention Studies (P30 MH062246) and the UCSF-Gladstone Center for AIDS Research (CFAR), an NIH-funded programme (P30 AI027763).

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on reasonable request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

REFERENCES

1. Poteat T, Scheim A, Xavier J, Reisner S, Baral S. Global epidemiology of HIV infection and related syndemics affecting transgender people. J Acquir Immune Defic Syndr. 2016;72(3):S210-9

2. Stutterheim SE, van Dijk M, Wang H, Jonas KJ. The worldwide burden of HIV in transgender individuals: an updated systematic review and meta-analysis. PLoS One. 2021;16(12):e0260063.

Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health. 2019;109(1):e1–8.
 Centers for Disease Control and Prevention. HIV infection, risk, prevention, and testing behaviors among transgender women. National HIV behavioral surveillance 7 U.S. cities, 2019–2020. HIV Surveillance Special Report 27. 2021.

5. Centers for Disease Control and Prevention. HIV surveillance report. 2018 (Updated). 2020 [cited 2020 May 8]. Available from: https://www.cdc.gov/hiv/ pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-updated-vol-31.pdf

6. Centers for Disease Control and Prevention. Transgender women involved in strategies for transformation (TWIST). 2021 [cited 2021 October 10]. Available from: https://www.cdc.gov/hiv/effective-interventions/treat/twist/index.html.

 Collier KL, Colarossi LG, Hazel DS, Watson K, Wyatt GE. Healing our women for transgender women: adaptation, acceptability, and pilot testing. AIDS Educ Prev. 2015;27(5):418–31.

8. Garofalo R, Kuhns LM, Reisner SL, Mimiaga MJ. Behavioral interventions to prevent HIV transmission and acquisition for transgender women: a critical review. J Acquir Immune Defic Syndr. 2016;72(3):S220–5.

9. Martinez O, Lopez N, Woodard T, Rodriguez-Madera S, Icard L. Transhealth Information Project: a peer-led HIV prevention intervention to promote HIV protection for individuals of transgender experience. Health Soc Work. 2019;44(2):104–12.

10. Reback CJ, Clark K, Fletcher JB. TransAction: a homegrown, theory-based, HIV risk reduction intervention for transgender women experiencing multiple health disparities. Sex Res Social Policy. 2019;16(4):408–18.

11. Sevelius JM, Neilands TB, Dilworth S, Castro D, Johnson MO. Sheroes: feasibility and acceptability of a community-driven, group-level HIV intervention program for transgender women. AIDS Behav. 2020;24(5):1551–9.

12. Skeen SJ, Cain D, Gamarel KE, Hightow-Weidman L, Reback CJ. mHealth for transgender and gender-expansive youth: harnessing gender-affirmative crossdisciplinary innovations to advance HIV prevention and care interventions. Mhealth. 2021;7:37.

13. Dinno A. Homicide rates of transgender individuals in the United States: 2010–2014. Am J Public Health. 2017;107(9):1441–7.

14. Human Rights Campaign. An epidemic of violence: fatal violence against transgender and gender non-conforming people in the U.S. in 2020. [Cited 2021 October 19]. Available from: https://reports.hrc.org/an-epidemic-of-violence-fatal-violence-against-transgender-and-gender-non-confirming-people-in-the-united-states-in-2020

15. Wirtz AL, Poteat TC, Malik M, Glass N. Gender-based violence against transgender people in the United States: a call for research and programming. Trauma Violence Abuse. 2020;21(2):227–41.

16. Xavier J. The orphans of the epidemic: transgender women of color. AIDS Behav. 2021;25(Suppl 1):1–2.

17. Berger MT. Coining intersectional stigma: historical erasures and the future. Am J Public Health. 2022;112(S4):S338-9.

18. Xavier J, Honnold JA, Bradford J. The health, health-related needs, and lifecourse experiences of transgender Virginians. Richmond, VA: Virginia HIV Community Planning Committee and Virginia Department of Health; 2007.

19. Reback C, Simon P, Bemis C, Gatson B. The Los Angeles Transgender Health Study: community report. Los Angeles, CA: University of California at Los Angeles; 2001.

20. Kenagy GP, Bostwick WB. Health and social service needs of transgender people in Chicago. Int J Transgend. 2005;8(2/3):57–66.

21. Kenagy GP. The health and social service needs of transgender people in Philadelphia. Int J Transgend. 2005;8(2/3):49–56.

22. Health Resources and Services Administration. Ryan White HIV/AIDS Program annual client-level data report 2020. 2021. Accessed December 20, 2021. Available from: https://hab.hrsa.gov/sites/default/files/hab/data/datareports/ RWHAP-annual-client-level-data-report-2020.pdf

23. Klein PW, Psihopaidas D, Xavier J, Cohen SM. HIV-related outcome disparities between transgender women living with HIV and cisgender people living with HIV served by the Health Resources and Services Administration's Ryan White HIV/AIDS Program: a retrospective study. PLoS Med. 2020;17(5):e1003125.

24. Thomas JA, Irvine MK, Xia Q, Harriman GA. Service utilization and HIV outcomes among transgender women receiving Ryan White Part A services in New York City. PLoS One. 2021;16(7):e0253444.

Brady RE, Singer B, Marconi KM. Special Projects of National Significance Program: ten models of adolescent HIV care. J Adolesc Health. 1998;23(2 Suppl):1–4.
 Health Resources and Services Administration. Part F: Special Projects of National Significance (SPNS) Program. Accessed October 19, 2021. Available from: https://hab.hrsa.gov/about-ryan-white-hivaids-program/part-f-special-projects-national-significance-spns-program.

27. Herwehe J, Wilbright W, Abrams A, Bergson S, Foxhood J, Kaiser M, et al. Implementation of an innovative, integrated electronic medical record (EMR) and public health information exchange for HIV/AIDS. J Am Med Inform Assoc. 2012;19(3):448–52.

28. Weiss L, Egan JE, Botsko M, Netherland J, Fiellin DA, Finkelstein R. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment. Acquir Immune Defic Syndr. 2011;56(1):S7–13.

29. Blank AE, Ryerson Espino SL, Eastwood B, Matoff-Stepp S, Xavier J; Women of Color Initiative. The HIV/AIDS women of color initiative improving access to and quality of care for women of color. J Health Care Poor Underserved. 2013;24(1):15–26.

30. Bradford JB, Coleman S, Cunningham W. HIV system navigation: an emerging model to improve HIV care access. AIDS Patient Care STDs. 2007;21(1):S49–58.

31. Jordan AO, Cohen LR, Harriman G, Teixeira PA, Cruzado-Quinones J, Venters H. Transitional care coordination in New York City jails: facilitating linkages to care for people with HIV returning home from Rikers Island. AIDS Behav. 2013;17(2):S212–9.

32. Sauceda JA, Brooks RA, Xavier J, Maiorana A, Georgetti Gomez L, Zamudio-Haas S, et al. From theory to application: a description of transnationalism in culturally-appropriate HIV interventions of outreach, access, and retention among Latino/a populations. J Immigr Minor Health. 2019;21(2):332–45.

33. Koester KA, Fuller SM, Maiorana A, Steward WT, Zamudio-Haas S, Xavier J, et al. Implementing multi-level interventions to improve HIV testing, linkageto- and retention-in-care interventions. J Health Care Poor Underserved. 2016;27(3):1234–51.

34. Rebchook G, Keatley J, Contreras R, Perloff J, Molano LF, Reback CJ, et al. The Transgender Women of Color Initiative: implementing and evaluating innovative interventions to enhance engagement and retention in HIV care. Am J Public Health. 2017;107(2):224–9.

35. Psihopaidas D, Cohen SM, West T, Avery L, Dempsey A, Brown K, et al. Implementation science and the Health Resources and Services Administration's Ryan White HIV/AIDS Program's work towards ending the HIV epidemic in the United States. PLoS Med. 2020;17(11):e1003128.

36. Health Resources and Services Administration. SPNS Transgender Women of Color Initiative: Project Interventions Manuals, November 14, 2018. Accessed November 19, 2018. Available from: https://targethiv.org/library/spnstransgender-women-color-initiative-manual.

37. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal , et al. The RED-Cap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.

38. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.

39. Sevelius JM, Xavier J, Chakravarty D, Keatley J, Shade S, Rebchook G, et al. Correlates of engagement in HIV care among transgender women of color in the United States of America. AIDS Behav. 2021;25(1):3–12.

40. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1994;10(2):77–84.

41. Kohout FJ, Berkman LF, Evans DA, Cornoni-Huntley J. Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) depression symptoms index. J Aging Health. 1993;5(2):179–93.

42. Zhang W, O'Brien N, Forrest JI, Salters KA, Patterson TL, Montaner JS, et al. Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada. PLoS One. 2012;7(7):e40793.

43. Bradford J, Reisner SL, Honnold JA, Xavier J. Experiences of transgenderrelated discrimination and implications for health: results from the Virginia Transgender Health Initiative Study. Am J Public Health. 2013;103(10):1820–9.

Jefferson K, Neilands T, Sevelius J. Transgender women of color: discrimination and depression symptoms. Ethn Inequal Health Soc Care. 2013;6(4):121–36.
 Johnson MO, Rose CD, Dilworth SE, Neilands TB. Advances in the conceptualization and measurement of Health Care Empowerment: development and validation of the Health Care Empowerment inventory. PLoS One. 2012;7(9): e45692.

46. Health Resources and Services Administration. Ryan White HIV/AIDS Program Annual Client-Level Data Report 2014. 2015. Accessed February 12, 2016. Available from: http://hab.hrsa.gov/data/servicesdelivered/2014RWHAPDataReport.pdf.

47. SAS Institute Inc. SAS OnlineDoc® 9.4. Cary, NC: SAS Institute Inc.; 2013.

48. Reback CJ, Ferlito D, Kisler KA, Fletcher JB. Recruiting, linking, and retaining high-risk transgender women into HIV prevention and care services: an overview of barriers, strategies, and lessons learned. Int J Transgend. 2015;16(4):209–21.

49. Lacombe-Duncan A. An intersectional perspective on access to HIV-related healthcare for transgender women. Transgend Health. 2016;1(1):137-41

50. Maiorana A, Sevelius J, Keatley J, Rebchook G. "She is like a sister to me." Gender-affirming services and relationships are key to the implementation of HIV care engagement interventions with transgender women of color. AIDS Behav. 2021;25(1):72–83.

51. Poteat T, Wirtz AL, Reisner S. Strategies for engaging transgender populations in HIV prevention and care. Curr Opin HIV AIDS. 2019;14(5):393–400.

52. Sievwright KM, Stangl AL, Nyblade L, Lippman SA, Logie CH, Veras M, et al. An expanded definition of intersectional stigma for public health research and praxis. Am J Public Health. 2022;112(S4):S356–61.

53. UNAIDS. Global AIDS Strategy 2021–2026. End inequalities. End AIDS. 2021. Accessed January 6, 2022. Available from: https://www.unaids.org/sites/ default/files/media_asset/global-AIDS-strategy-2021-2026_en.pdf.

54. Hirshfield S, Contreras J, Luebe RQ, Swartz JA, Scheinmann R, Reback CJ, et al. Engagement in HIV care among New York City transgender women of color: findings from the peer-led, TWEET intervention, a SPNS Trans Women of Color Initiative. AIDS Behav. 2021;25(1):20–30.

55. Eastwood EA, Nace AJ, Hirshfield S, Birnbaum JM. Young transgender women of color: homelessness, poverty, childhood sexual abuse and implications for HIV care. AIDS Behav. 2021;25(1):96–106.

56. Swartz JA, Ducheny K, Holloway T, Stokes L, Willis S, Kuhns LM. A latent class analysis of chronic health conditions among HIV-positive transgender women of color. AIDS Behav. 2021;25(1):52–63.

57. Kuhns LM, Hotton AL, Perloff J, Paul J, Parker C, Muldoon AL, et al. Evaluation of Translife Care: an intervention to address social determinants of engagement in HIV care among transgender women of color. AIDS Behav. 2021;25(1):13–9.

58. Wilson EC, Turner C, Arayasirikul S, Woods T, Tryon J, Franza K, et al. HIV care engagement among trans women of color in San Francisco Bay Area demonstration projects: findings from the Brandy Martell Project and TransAccess. AIDS Behav. 2021;25(1):31–9.

59. Nemoto T, Iwamoto M, Suico S, Stanislaus V, Piroth K. Sociocultural contexts of access to HIV primary care and participant experience with an intervention project: African American transgender women living with HIV in Alameda County, California. AIDS Behav. 2021;25(1):84–95.

60. Galvan FH, Chen YT, Contreras R, O'Connell B. Violence inflicted on Latina transgender women living with HIV: rates and associated factors by perpetrator type. AIDS Behav. 2021;25(1):116–26.

61. Reback CJ, Kisler KA, Fletcher JB. A novel adaptation of peer health navigation and contingency management for advancement along the HIV care continuum among transgender women of color. AIDS Behav. 2021;25(1):40–51.

SUPPORTING INFORMATION

Additional information may be found under the Supporting Information tab for this article:

Supplemental Table 1. Adjusted Primary Outcomes.